Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial

Coronary plaques that are prone to rupture and cause adverse cardiac events are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins can halt the progression of coronary atherosclerosis; however, the effect of the proprotein convertase subtilisin kexin type 9 inh...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	JAMA : the journal of the American Medical Association Ročník 327; číslo 18; s. 1771
Hlavní autoři:	Räber, Lorenz, Ueki, Yasushi, Otsuka, Tatsuhiko, Losdat, Sylvain, Häner, Jonas D, Lonborg, Jacob, Fahrni, Gregor, Iglesias, Juan F, van Geuns, Robert-Jan, Ondracek, Anna S, Radu Juul Jensen, Maria D, Zanchin, Christian, Stortecky, Stefan, Spirk, David, Siontis, George C M, Saleh, Lanja, Matter, Christian M, Daemen, Joost, Mach, François, Heg, Dik, Windecker, Stephan, Engstrøm, Thomas, Lang, Irene M, Koskinas, Konstantinos C
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 10.05.2022
Témata:	Aged Antibodies, Monoclonal, Humanized - therapeutic use Cholesterol, LDL Coronary Artery Disease - complications Coronary Artery Disease - diagnostic imaging Coronary Artery Disease - drug therapy Double-Blind Method Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Male Middle Aged Myocardial Infarction - complications Myocardial Infarction - drug therapy PCSK9 Inhibitors - therapeutic use Plaque, Atherosclerotic - complications Plaque, Atherosclerotic - diagnostic imaging Plaque, Atherosclerotic - drug therapy Treatment Outcome
ISSN:	1538-3598, 1538-3598
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Coronary plaques that are prone to rupture and cause adverse cardiac events are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins can halt the progression of coronary atherosclerosis; however, the effect of the proprotein convertase subtilisin kexin type 9 inhibitor alirocumab added to statin therapy on plaque burden and composition remains largely unknown. To determine the effects of alirocumab on coronary atherosclerosis using serial multimodality intracoronary imaging in patients with acute myocardial infarction. The PACMAN-AMI double-blind, placebo-controlled, randomized clinical trial (enrollment: May 9, 2017, through October 7, 2020; final follow-up: October 13, 2021) enrolled 300 patients undergoing percutaneous coronary intervention for acute myocardial infarction at 9 academic European hospitals. Patients were randomized to receive biweekly subcutaneous alirocumab (150 mg; n = 148) or placebo (n = 152), initiated less than 24 hours after urgent percutaneous coronary intervention of the culprit lesion, for 52 weeks in addition to high-intensity statin therapy (rosuvastatin, 20 mg). Intravascular ultrasonography (IVUS), near-infrared spectroscopy, and optical coherence tomography were serially performed in the 2 non-infarct-related coronary arteries at baseline and after 52 weeks. The primary efficacy end point was the change in IVUS-derived percent atheroma volume from baseline to week 52. Two powered secondary end points were changes in near-infrared spectroscopy-derived maximum lipid core burden index within 4 mm (higher values indicating greater lipid content) and optical coherence tomography-derived minimal fibrous cap thickness (smaller values indicating thin-capped, vulnerable plaques) from baseline to week 52. Among 300 randomized patients (mean [SD] age, 58.5 [9.7] years; 56 [18.7%] women; mean [SD] low-density lipoprotein cholesterol level, 152.4 [33.8] mg/dL), 265 (88.3%) underwent serial IVUS imaging in 537 arteries. At 52 weeks, mean change in percent atheroma volume was -2.13% with alirocumab vs -0.92% with placebo (difference, -1.21% [95% CI, -1.78% to -0.65%], P < .001). Mean change in maximum lipid core burden index within 4 mm was -79.42 with alirocumab vs -37.60 with placebo (difference, -41.24 [95% CI, -70.71 to -11.77]; P = .006). Mean change in minimal fibrous cap thickness was 62.67 μm with alirocumab vs 33.19 μm with placebo (difference, 29.65 μm [95% CI, 11.75-47.55]; P = .001). Adverse events occurred in 70.7% of patients treated with alirocumab vs 72.8% of patients receiving placebo. Among patients with acute myocardial infarction, the addition of subcutaneous biweekly alirocumab, compared with placebo, to high-intensity statin therapy resulted in significantly greater coronary plaque regression in non-infarct-related arteries after 52 weeks. Further research is needed to understand whether alirocumab improves clinical outcomes in this population. ClinicalTrials.gov Identifier: NCT03067844.
AbstractList	Coronary plaques that are prone to rupture and cause adverse cardiac events are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins can halt the progression of coronary atherosclerosis; however, the effect of the proprotein convertase subtilisin kexin type 9 inhibitor alirocumab added to statin therapy on plaque burden and composition remains largely unknown. To determine the effects of alirocumab on coronary atherosclerosis using serial multimodality intracoronary imaging in patients with acute myocardial infarction. The PACMAN-AMI double-blind, placebo-controlled, randomized clinical trial (enrollment: May 9, 2017, through October 7, 2020; final follow-up: October 13, 2021) enrolled 300 patients undergoing percutaneous coronary intervention for acute myocardial infarction at 9 academic European hospitals. Patients were randomized to receive biweekly subcutaneous alirocumab (150 mg; n = 148) or placebo (n = 152), initiated less than 24 hours after urgent percutaneous coronary intervention of the culprit lesion, for 52 weeks in addition to high-intensity statin therapy (rosuvastatin, 20 mg). Intravascular ultrasonography (IVUS), near-infrared spectroscopy, and optical coherence tomography were serially performed in the 2 non-infarct-related coronary arteries at baseline and after 52 weeks. The primary efficacy end point was the change in IVUS-derived percent atheroma volume from baseline to week 52. Two powered secondary end points were changes in near-infrared spectroscopy-derived maximum lipid core burden index within 4 mm (higher values indicating greater lipid content) and optical coherence tomography-derived minimal fibrous cap thickness (smaller values indicating thin-capped, vulnerable plaques) from baseline to week 52. Among 300 randomized patients (mean [SD] age, 58.5 [9.7] years; 56 [18.7%] women; mean [SD] low-density lipoprotein cholesterol level, 152.4 [33.8] mg/dL), 265 (88.3%) underwent serial IVUS imaging in 537 arteries. At 52 weeks, mean change in percent atheroma volume was -2.13% with alirocumab vs -0.92% with placebo (difference, -1.21% [95% CI, -1.78% to -0.65%], P < .001). Mean change in maximum lipid core burden index within 4 mm was -79.42 with alirocumab vs -37.60 with placebo (difference, -41.24 [95% CI, -70.71 to -11.77]; P = .006). Mean change in minimal fibrous cap thickness was 62.67 μm with alirocumab vs 33.19 μm with placebo (difference, 29.65 μm [95% CI, 11.75-47.55]; P = .001). Adverse events occurred in 70.7% of patients treated with alirocumab vs 72.8% of patients receiving placebo. Among patients with acute myocardial infarction, the addition of subcutaneous biweekly alirocumab, compared with placebo, to high-intensity statin therapy resulted in significantly greater coronary plaque regression in non-infarct-related arteries after 52 weeks. Further research is needed to understand whether alirocumab improves clinical outcomes in this population. ClinicalTrials.gov Identifier: NCT03067844. Coronary plaques that are prone to rupture and cause adverse cardiac events are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins can halt the progression of coronary atherosclerosis; however, the effect of the proprotein convertase subtilisin kexin type 9 inhibitor alirocumab added to statin therapy on plaque burden and composition remains largely unknown.ImportanceCoronary plaques that are prone to rupture and cause adverse cardiac events are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins can halt the progression of coronary atherosclerosis; however, the effect of the proprotein convertase subtilisin kexin type 9 inhibitor alirocumab added to statin therapy on plaque burden and composition remains largely unknown.To determine the effects of alirocumab on coronary atherosclerosis using serial multimodality intracoronary imaging in patients with acute myocardial infarction.ObjectiveTo determine the effects of alirocumab on coronary atherosclerosis using serial multimodality intracoronary imaging in patients with acute myocardial infarction.The PACMAN-AMI double-blind, placebo-controlled, randomized clinical trial (enrollment: May 9, 2017, through October 7, 2020; final follow-up: October 13, 2021) enrolled 300 patients undergoing percutaneous coronary intervention for acute myocardial infarction at 9 academic European hospitals.Design, Setting, and ParticipantsThe PACMAN-AMI double-blind, placebo-controlled, randomized clinical trial (enrollment: May 9, 2017, through October 7, 2020; final follow-up: October 13, 2021) enrolled 300 patients undergoing percutaneous coronary intervention for acute myocardial infarction at 9 academic European hospitals.Patients were randomized to receive biweekly subcutaneous alirocumab (150 mg; n = 148) or placebo (n = 152), initiated less than 24 hours after urgent percutaneous coronary intervention of the culprit lesion, for 52 weeks in addition to high-intensity statin therapy (rosuvastatin, 20 mg).InterventionsPatients were randomized to receive biweekly subcutaneous alirocumab (150 mg; n = 148) or placebo (n = 152), initiated less than 24 hours after urgent percutaneous coronary intervention of the culprit lesion, for 52 weeks in addition to high-intensity statin therapy (rosuvastatin, 20 mg).Intravascular ultrasonography (IVUS), near-infrared spectroscopy, and optical coherence tomography were serially performed in the 2 non-infarct-related coronary arteries at baseline and after 52 weeks. The primary efficacy end point was the change in IVUS-derived percent atheroma volume from baseline to week 52. Two powered secondary end points were changes in near-infrared spectroscopy-derived maximum lipid core burden index within 4 mm (higher values indicating greater lipid content) and optical coherence tomography-derived minimal fibrous cap thickness (smaller values indicating thin-capped, vulnerable plaques) from baseline to week 52.Main Outcomes and MeasuresIntravascular ultrasonography (IVUS), near-infrared spectroscopy, and optical coherence tomography were serially performed in the 2 non-infarct-related coronary arteries at baseline and after 52 weeks. The primary efficacy end point was the change in IVUS-derived percent atheroma volume from baseline to week 52. Two powered secondary end points were changes in near-infrared spectroscopy-derived maximum lipid core burden index within 4 mm (higher values indicating greater lipid content) and optical coherence tomography-derived minimal fibrous cap thickness (smaller values indicating thin-capped, vulnerable plaques) from baseline to week 52.Among 300 randomized patients (mean [SD] age, 58.5 [9.7] years; 56 [18.7%] women; mean [SD] low-density lipoprotein cholesterol level, 152.4 [33.8] mg/dL), 265 (88.3%) underwent serial IVUS imaging in 537 arteries. At 52 weeks, mean change in percent atheroma volume was -2.13% with alirocumab vs -0.92% with placebo (difference, -1.21% [95% CI, -1.78% to -0.65%], P < .001). Mean change in maximum lipid core burden index within 4 mm was -79.42 with alirocumab vs -37.60 with placebo (difference, -41.24 [95% CI, -70.71 to -11.77]; P = .006). Mean change in minimal fibrous cap thickness was 62.67 μm with alirocumab vs 33.19 μm with placebo (difference, 29.65 μm [95% CI, 11.75-47.55]; P = .001). Adverse events occurred in 70.7% of patients treated with alirocumab vs 72.8% of patients receiving placebo.ResultsAmong 300 randomized patients (mean [SD] age, 58.5 [9.7] years; 56 [18.7%] women; mean [SD] low-density lipoprotein cholesterol level, 152.4 [33.8] mg/dL), 265 (88.3%) underwent serial IVUS imaging in 537 arteries. At 52 weeks, mean change in percent atheroma volume was -2.13% with alirocumab vs -0.92% with placebo (difference, -1.21% [95% CI, -1.78% to -0.65%], P < .001). Mean change in maximum lipid core burden index within 4 mm was -79.42 with alirocumab vs -37.60 with placebo (difference, -41.24 [95% CI, -70.71 to -11.77]; P = .006). Mean change in minimal fibrous cap thickness was 62.67 μm with alirocumab vs 33.19 μm with placebo (difference, 29.65 μm [95% CI, 11.75-47.55]; P = .001). Adverse events occurred in 70.7% of patients treated with alirocumab vs 72.8% of patients receiving placebo.Among patients with acute myocardial infarction, the addition of subcutaneous biweekly alirocumab, compared with placebo, to high-intensity statin therapy resulted in significantly greater coronary plaque regression in non-infarct-related arteries after 52 weeks. Further research is needed to understand whether alirocumab improves clinical outcomes in this population.Conclusions and RelevanceAmong patients with acute myocardial infarction, the addition of subcutaneous biweekly alirocumab, compared with placebo, to high-intensity statin therapy resulted in significantly greater coronary plaque regression in non-infarct-related arteries after 52 weeks. Further research is needed to understand whether alirocumab improves clinical outcomes in this population.ClinicalTrials.gov Identifier: NCT03067844.Trial RegistrationClinicalTrials.gov Identifier: NCT03067844.
Author	Heg, Dik Fahrni, Gregor Windecker, Stephan Siontis, George C M Mach, François Radu Juul Jensen, Maria D van Geuns, Robert-Jan Otsuka, Tatsuhiko Zanchin, Christian Stortecky, Stefan Spirk, David Matter, Christian M Engstrøm, Thomas Losdat, Sylvain Räber, Lorenz Koskinas, Konstantinos C Ueki, Yasushi Saleh, Lanja Daemen, Joost Häner, Jonas D Iglesias, Juan F Lonborg, Jacob Ondracek, Anna S Lang, Irene M
Author_xml	– sequence: 1 givenname: Lorenz surname: Räber fullname: Räber, Lorenz organization: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland – sequence: 2 givenname: Yasushi surname: Ueki fullname: Ueki, Yasushi organization: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland – sequence: 3 givenname: Tatsuhiko surname: Otsuka fullname: Otsuka, Tatsuhiko organization: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland – sequence: 4 givenname: Sylvain surname: Losdat fullname: Losdat, Sylvain organization: CTU Bern, University of Bern, Bern, Switzerland – sequence: 5 givenname: Jonas D surname: Häner fullname: Häner, Jonas D organization: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland – sequence: 6 givenname: Jacob surname: Lonborg fullname: Lonborg, Jacob organization: Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark – sequence: 7 givenname: Gregor surname: Fahrni fullname: Fahrni, Gregor organization: Department of Cardiology, University Hospital Basel, Basel, Switzerland – sequence: 8 givenname: Juan F surname: Iglesias fullname: Iglesias, Juan F organization: Division of Cardiology, University Hospital Geneva, Geneva, Switzerland – sequence: 9 givenname: Robert-Jan surname: van Geuns fullname: van Geuns, Robert-Jan organization: Department of Cardiology, Radboud UMC, Nijmegen, the Netherlands – sequence: 10 givenname: Anna S surname: Ondracek fullname: Ondracek, Anna S organization: Department of Cardiology, Medical University of Vienna, Vienna, Austria – sequence: 11 givenname: Maria D surname: Radu Juul Jensen fullname: Radu Juul Jensen, Maria D organization: Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark – sequence: 12 givenname: Christian surname: Zanchin fullname: Zanchin, Christian organization: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland – sequence: 13 givenname: Stefan surname: Stortecky fullname: Stortecky, Stefan organization: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland – sequence: 14 givenname: David surname: Spirk fullname: Spirk, David organization: Department of Pharmacology, Bern University Hospital, Bern, Switzerland, and Sanofi, Switzerland – sequence: 15 givenname: George C M surname: Siontis fullname: Siontis, George C M organization: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland – sequence: 16 givenname: Lanja surname: Saleh fullname: Saleh, Lanja organization: Institute of Clinical Chemistry, Zurich University Hospital, Zurich, Switzerland – sequence: 17 givenname: Christian M surname: Matter fullname: Matter, Christian M organization: Department of Cardiology, Zurich University Hospital, Zurich, Switzerland – sequence: 18 givenname: Joost surname: Daemen fullname: Daemen, Joost organization: Department of Cardiology, Erasmus University Medical Center, Rotterdam, the Netherlands – sequence: 19 givenname: François surname: Mach fullname: Mach, François organization: Division of Cardiology, University Hospital Geneva, Geneva, Switzerland – sequence: 20 givenname: Dik surname: Heg fullname: Heg, Dik organization: CTU Bern, University of Bern, Bern, Switzerland – sequence: 21 givenname: Stephan surname: Windecker fullname: Windecker, Stephan organization: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland – sequence: 22 givenname: Thomas surname: Engstrøm fullname: Engstrøm, Thomas organization: Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark – sequence: 23 givenname: Irene M surname: Lang fullname: Lang, Irene M organization: Department of Cardiology, Medical University of Vienna, Vienna, Austria – sequence: 24 givenname: Konstantinos C surname: Koskinas fullname: Koskinas, Konstantinos C organization: Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35368058$$D View this record in MEDLINE/PubMed
BookMark	eNpNkE1P3DAQhq0KVD7aK8dqjlyy2E6cOL1FES0rsYBgqx5Xjj9Yo8RebOew_Kj-xhoBEnOYGY2e99XMnKAD551G6IzgBcGYXDyJSSwopnTBKOFf0DFhJS9K1vKDT_0ROonxCecgZfMVHZWsrDlm_Bj9uzRGywTeQDfa4OU8iQE6pbSC5OHKPm6LpUvaRZv28JBEsg7WWx3Ebg_eQe-DdyLsoUt56KMcX7ONkLG7DGuXIvy1aQudnJOG1d5LEZQVIyydEUEm693PV0e46_pVd1N0qyXcC6f8ZF_yEv1onZUZX4cs-oYOjRij_v5eT9GfX5fr_qq4vv297LvrQpRtk4paDMwwWnEzcIXzgZw2guGqZI3SojJM6dpI1gymbbIAk5qwQRveqJLIqh3oKTp_890F_zzrmDaTjVKPo3Daz3FD66puK8IYz-iPd3QeJq02u2Cn_JDNx4_pf7eGgio
CitedBy_id	crossref_primary_10_1016_j_jjcc_2024_05_011 crossref_primary_10_3390_biomedicines10112849 crossref_primary_10_1016_j_jacasi_2025_05_016 crossref_primary_10_3390_jcm12134550 crossref_primary_10_1016_j_ijcard_2025_133327 crossref_primary_10_1093_eurheartj_ehaf337 crossref_primary_10_1016_j_jacc_2025_04_013 crossref_primary_10_1093_eurjpc_zwaf532 crossref_primary_10_1016_j_jacc_2023_08_038 crossref_primary_10_1186_s12909_024_05544_6 crossref_primary_10_1007_s12928_024_00994_7 crossref_primary_10_1016_j_jcin_2023_07_043 crossref_primary_10_1186_s12872_025_05005_y crossref_primary_10_1016_j_tem_2024_12_001 crossref_primary_10_1016_j_cellsig_2022_110471 crossref_primary_10_1038_s41598_023_38578_9 crossref_primary_10_1161_CIRCIMAGING_123_016206 crossref_primary_10_3390_jcm13051251 crossref_primary_10_1016_j_jacbts_2025_05_004 crossref_primary_10_3390_hearts5030027 crossref_primary_10_1097_MCA_0000000000001331 crossref_primary_10_1016_j_cjca_2022_05_021 crossref_primary_10_1016_j_jacc_2023_01_030 crossref_primary_10_1016_j_jjcc_2025_03_001 crossref_primary_10_1016_j_hlc_2024_07_012 crossref_primary_10_1016_j_jacasi_2025_01_009 crossref_primary_10_3389_fphar_2025_1626681 crossref_primary_10_1016_j_isci_2024_110641 crossref_primary_10_1016_j_amjcard_2023_12_056 crossref_primary_10_1038_s41569_023_00979_8 crossref_primary_10_3390_molecules28186438 crossref_primary_10_3390_photonics10020158 crossref_primary_10_3389_fphar_2024_1393333 crossref_primary_10_1038_s42255_024_01115_7 crossref_primary_10_1080_21645515_2023_2266926 crossref_primary_10_1016_j_ajpc_2025_101022 crossref_primary_10_1186_s12944_024_02294_8 crossref_primary_10_1016_j_atherosclerosis_2024_117504 crossref_primary_10_1136_openhrt_2023_002343 crossref_primary_10_3390_biom13081236 crossref_primary_10_3390_jcm12216952 crossref_primary_10_1097_MS9_0000000000001945 crossref_primary_10_1016_j_phrs_2025_107635 crossref_primary_10_2459_JCM_0000000000001777 crossref_primary_10_3390_jcm13071882 crossref_primary_10_1093_eurheartjsupp_suae010 crossref_primary_10_1097_MCA_0000000000001464 crossref_primary_10_1093_eurheartjsupp_suad040 crossref_primary_10_1161_JAHA_123_034458 crossref_primary_10_1007_s40256_025_00733_0 crossref_primary_10_1093_cvr_cvaf100 crossref_primary_10_1093_eurheartj_ehae385 crossref_primary_10_1016_j_ajpc_2024_100918 crossref_primary_10_1093_eurjpc_zwad248 crossref_primary_10_1159_000538044 crossref_primary_10_3389_fendo_2023_1218968 crossref_primary_10_3390_jcm12185807 crossref_primary_10_1016_j_jcmg_2025_04_002 crossref_primary_10_3390_jcdd10060260 crossref_primary_10_1016_j_ejim_2025_106442 crossref_primary_10_1016_j_atherosclerosis_2025_120433 crossref_primary_10_1186_s12933_023_01814_7 crossref_primary_10_3390_metabo13080916 crossref_primary_10_1016_j_amjcard_2023_12_035 crossref_primary_10_1093_eurheartj_ehac750 crossref_primary_10_1038_s41569_022_00706_9 crossref_primary_10_1016_j_ejim_2023_02_010 crossref_primary_10_1055_a_2156_7872 crossref_primary_10_2147_IJGM_S460305 crossref_primary_10_1016_j_jacadv_2023_100825 crossref_primary_10_3390_lipidology2030014 crossref_primary_10_1016_j_jacl_2024_09_014 crossref_primary_10_1016_j_atherosclerosis_2024_118618 crossref_primary_10_1038_s44161_023_00412_w crossref_primary_10_1093_eurheartjsupp_suad100 crossref_primary_10_3389_fcvm_2023_1095806 crossref_primary_10_1177_03000605251361962 crossref_primary_10_3390_jcm13041097 crossref_primary_10_3389_fphar_2024_1413123 crossref_primary_10_3390_ijms24065155 crossref_primary_10_1016_j_jcin_2024_07_007 crossref_primary_10_3389_fcvm_2022_1016802 crossref_primary_10_3390_biomedicines13071723 crossref_primary_10_3390_ph17070919 crossref_primary_10_1093_eurjpc_zwaf211 crossref_primary_10_1093_cvr_cvaf087 crossref_primary_10_1177_10742484231186855 crossref_primary_10_1016_j_jacasi_2023_10_001 crossref_primary_10_1126_scitranslmed_ado6467 crossref_primary_10_1016_j_clinthera_2022_04_010 crossref_primary_10_15829_1560_4071_2024_6038 crossref_primary_10_1097_HCO_0000000000001080 crossref_primary_10_1016_j_pharmthera_2025_108812 crossref_primary_10_1002_clc_24329 crossref_primary_10_1038_s44161_023_00409_5 crossref_primary_10_3390_cancers15051397 crossref_primary_10_1024_0301_1526_a001202 crossref_primary_10_3390_jcm13175040 crossref_primary_10_3390_jcm13072043 crossref_primary_10_3390_jcm13195791 crossref_primary_10_4244_EIJ_D_24_01065 crossref_primary_10_1007_s00508_024_02402_9 crossref_primary_10_1016_j_ejim_2023_04_026 crossref_primary_10_1097_MOL_0000000000000935 crossref_primary_10_1038_s41598_023_32638_w crossref_primary_10_1093_eurheartj_ehae430 crossref_primary_10_1161_CIRCULATIONAHA_124_071855 crossref_primary_10_1161_ATVBAHA_124_321504 crossref_primary_10_1093_ehjcvp_pvac064 crossref_primary_10_1136_heartjnl_2024_325408 crossref_primary_10_1007_s10557_024_07587_9 crossref_primary_10_1016_j_amjcard_2022_11_048 crossref_primary_10_1016_j_ijcard_2023_131330 crossref_primary_10_1016_j_jcmg_2025_02_005 crossref_primary_10_1111_eci_14272 crossref_primary_10_1016_j_jcmg_2025_02_003 crossref_primary_10_3390_life15081226 crossref_primary_10_3390_life14060679 crossref_primary_10_3233_CH_242172 crossref_primary_10_1007_s10565_025_09996_4 crossref_primary_10_1161_CIRCULATIONAHA_124_072950 crossref_primary_10_1016_j_atherosclerosis_2023_06_006 crossref_primary_10_1080_07853890_2024_2389470 crossref_primary_10_1007_s40256_024_00719_4 crossref_primary_10_1016_j_jcmg_2024_12_009 crossref_primary_10_1093_ehjcvp_pvaf007 crossref_primary_10_1186_s12872_023_03164_4 crossref_primary_10_1093_eurheartj_ehaf314 crossref_primary_10_1093_eurjpc_zwaf112 crossref_primary_10_3390_jcm14155451 crossref_primary_10_1016_j_jcmg_2024_12_004 crossref_primary_10_1001_jama_2022_11830 crossref_primary_10_3390_jcm13113096 crossref_primary_10_1016_j_clineuro_2024_108507 crossref_primary_10_1001_jama_2022_11833 crossref_primary_10_1186_s43044_024_00567_2 crossref_primary_10_1038_s41569_023_00947_2 crossref_primary_10_2174_0109298673262124231102042914 crossref_primary_10_1016_j_ahj_2024_06_004 crossref_primary_10_1016_j_carpath_2025_107736 crossref_primary_10_1016_j_phrs_2023_106738 crossref_primary_10_1093_ehjcvp_pvaf004 crossref_primary_10_1001_jama_2022_11836 crossref_primary_10_3389_fneur_2022_982147 crossref_primary_10_1016_j_amjcard_2023_07_032 crossref_primary_10_1161_CIRCULATIONAHA_124_073362 crossref_primary_10_1161_JAHA_122_028892 crossref_primary_10_1016_j_ijcard_2025_133580 crossref_primary_10_1161_CIRCULATIONAHA_122_062557 crossref_primary_10_3390_jcm14092992 crossref_primary_10_1016_j_tcm_2025_07_002 crossref_primary_10_1016_j_atherosclerosis_2025_120479 crossref_primary_10_1016_j_jacc_2023_02_038 crossref_primary_10_1016_j_biopha_2024_116870 crossref_primary_10_1016_j_ijcard_2024_131775 crossref_primary_10_1371_journal_pone_0302547 crossref_primary_10_1093_eurheartj_ehad486 crossref_primary_10_3390_ijms24098062 crossref_primary_10_1038_s41569_022_00769_8 crossref_primary_10_3389_fcvm_2022_1061346 crossref_primary_10_3390_ph17050568 crossref_primary_10_1002_lipd_12432 crossref_primary_10_3390_ijms24031966 crossref_primary_10_1016_j_cjca_2022_06_013 crossref_primary_10_1007_s00508_023_02296_z crossref_primary_10_1016_j_iccl_2022_10_007 crossref_primary_10_3390_biomedicines12112435 crossref_primary_10_1055_s_0044_1782161 crossref_primary_10_1172_JCI182939 crossref_primary_10_1007_s10554_022_02736_3 crossref_primary_10_1007_s40256_024_00651_7 crossref_primary_10_3390_ijerph192416899 crossref_primary_10_1016_j_ajpc_2022_100371 crossref_primary_10_54912_jci_2025_0026 crossref_primary_10_1007_s40265_024_01995_9 crossref_primary_10_1016_j_jacc_2023_02_008 crossref_primary_10_1186_s12920_024_01826_6 crossref_primary_10_1007_s10557_024_07622_9 crossref_primary_10_1007_s10554_025_03472_0 crossref_primary_10_1016_j_jacc_2025_02_007 crossref_primary_10_1080_14779072_2024_2398444 crossref_primary_10_1093_cvr_cvae191 crossref_primary_10_1093_eurheartj_ehaf615 crossref_primary_10_1016_j_ahj_2025_04_021 crossref_primary_10_2174_0109298673311105240902053715 crossref_primary_10_1007_s11883_022_01053_3 crossref_primary_10_1016_j_carrev_2022_08_008 crossref_primary_10_1016_j_artere_2025_500798 crossref_primary_10_1016_j_jacl_2024_12_019 crossref_primary_10_3389_fcvm_2024_1431398 crossref_primary_10_1002_clc_24243 crossref_primary_10_1007_s40256_023_00621_5 crossref_primary_10_1155_2022_7674366 crossref_primary_10_3389_fcvm_2023_1138787 crossref_primary_10_3390_diagnostics14151671 crossref_primary_10_7759_cureus_71365 crossref_primary_10_1016_j_prmedi_2024_10_005 crossref_primary_10_1186_s43044_025_00660_0 crossref_primary_10_1007_s00380_025_02571_1 crossref_primary_10_1016_j_ijcrp_2025_200440 crossref_primary_10_1016_j_ajpc_2025_101311 crossref_primary_10_3390_jcm11164716 crossref_primary_10_1016_j_arteri_2024_08_007 crossref_primary_10_1016_j_atherosclerosis_2025_120482 crossref_primary_10_1038_s44161_022_00085_x crossref_primary_10_1161_CIRCIMAGING_124_016683 crossref_primary_10_3390_jcm13020363 crossref_primary_10_1016_j_atherosclerosis_2025_119145 crossref_primary_10_1016_j_ijcard_2023_131659 crossref_primary_10_1097_FJC_0000000000001376 crossref_primary_10_1080_14779072_2023_2288169 crossref_primary_10_3390_jcm11226838 crossref_primary_10_3390_jcdd12080300 crossref_primary_10_1161_CIRCINTERVENTIONS_125_015529 crossref_primary_10_1053_j_jvca_2022_11_002 crossref_primary_10_3390_jcm14186445 crossref_primary_10_1038_s44161_025_00664_8 crossref_primary_10_3390_jcm14134562 crossref_primary_10_1007_s00392_024_02540_0 crossref_primary_10_1007_s11883_024_01243_1 crossref_primary_10_1016_j_ijcard_2024_132365 crossref_primary_10_1253_circrep_CR_25_0049 crossref_primary_10_1016_j_jacl_2024_07_001 crossref_primary_10_1016_j_jacc_2022_07_006 crossref_primary_10_1016_j_hipert_2024_12_002 crossref_primary_10_1161_JAHA_123_029707 crossref_primary_10_1177_1358863X231169324 crossref_primary_10_3390_life13030696 crossref_primary_10_3389_fcvm_2023_1148486 crossref_primary_10_1016_j_ejim_2024_08_010 crossref_primary_10_1016_j_ijcard_2025_133704 crossref_primary_10_1097_MD_0000000000040020 crossref_primary_10_1016_j_atherosclerosis_2024_118581 crossref_primary_10_1016_j_ajpc_2024_100645 crossref_primary_10_1007_s10557_023_07511_7 crossref_primary_10_1016_j_jcmg_2024_04_001 crossref_primary_10_4103_jpdtsm_jpdtsm_112_24 crossref_primary_10_4244_EIJ_D_24_00387 crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107633 crossref_primary_10_1186_s13098_023_01238_z crossref_primary_10_1186_s40364_024_00712_8 crossref_primary_10_1016_j_jacc_2023_11_029 crossref_primary_10_1186_s12933_023_01844_1 crossref_primary_10_3390_jcm14020305 crossref_primary_10_1007_s11883_024_01271_x crossref_primary_10_1016_j_jjcc_2022_07_003 crossref_primary_10_1016_j_amjcard_2023_10_043 crossref_primary_10_1093_eurjpc_zwae170 crossref_primary_10_1093_ehjdh_ztaf005 crossref_primary_10_1016_j_heliyon_2024_e38077 crossref_primary_10_1093_eurjpc_zwac309 crossref_primary_10_1016_S0140_6736_25_00055_8 crossref_primary_10_1097_MD_0000000000037416 crossref_primary_10_3390_jcm14051539 crossref_primary_10_1097_MOL_0000000000000954 crossref_primary_10_1007_s11428_023_01034_3 crossref_primary_10_1038_s44325_024_00006_w crossref_primary_10_1186_s12872_025_04634_7 crossref_primary_10_1093_eurheartj_ehaf190 crossref_primary_10_1080_14796678_2024_2367860 crossref_primary_10_1016_j_carrev_2023_07_003 crossref_primary_10_1016_j_revmed_2023_10_455 crossref_primary_10_1093_eurheartjsupp_suac099 crossref_primary_10_3390_life13030630 crossref_primary_10_3389_fphar_2025_1555508 crossref_primary_10_1007_s11883_023_01163_6 crossref_primary_10_1186_s12872_025_05070_3 crossref_primary_10_1007_s11886_022_01760_y crossref_primary_10_15829_1560_4071_2022_5282 crossref_primary_10_1186_s12959_024_00657_w crossref_primary_10_1161_CIRCULATIONAHA_124_069808 crossref_primary_10_1097_CP9_0000000000000099 crossref_primary_10_1080_14796678_2025_2450189 crossref_primary_10_1161_CIRCIMAGING_123_016482 crossref_primary_10_1080_14656566_2024_2444986 crossref_primary_10_1016_j_jacc_2024_11_009 crossref_primary_10_1016_j_carrev_2024_09_006 crossref_primary_10_1038_s44161_023_00405_9 crossref_primary_10_1097_MOL_0000000000000897 crossref_primary_10_1186_s12872_024_04057_w crossref_primary_10_1016_j_cjco_2025_06_021 crossref_primary_10_15829_1560_4071_2025_6306 crossref_primary_10_1016_j_cej_2023_144766 crossref_primary_10_7555_JBR_37_20230223 crossref_primary_10_1007_s40119_024_00384_3 crossref_primary_10_1186_s13063_024_08469_z crossref_primary_10_1097_MD_0000000000037637 crossref_primary_10_3390_genes16010098 crossref_primary_10_1080_14779072_2025_2476132 crossref_primary_10_1080_14656566_2023_2171788 crossref_primary_10_1186_s12933_022_01542_4 crossref_primary_10_1093_ehjopen_oeae055 crossref_primary_10_1161_CIRCULATIONAHA_123_063658 crossref_primary_10_2147_VHRM_S275739 crossref_primary_10_1177_23969873241231702 crossref_primary_10_1016_j_carrev_2023_09_010 crossref_primary_10_1007_s11886_022_01782_6 crossref_primary_10_1016_j_jscai_2025_103607 crossref_primary_10_3390_nu15061517 crossref_primary_10_1093_eurheartj_ehad191 crossref_primary_10_1186_s12967_024_05231_6 crossref_primary_10_1007_s11883_024_01241_3 crossref_primary_10_1016_j_jcmg_2023_02_002 crossref_primary_10_1016_j_jcmg_2024_04_019 crossref_primary_10_2459_JCM_0000000000001440 crossref_primary_10_1016_j_chemphyslip_2023_105325 crossref_primary_10_1093_eurheartjsupp_suad086 crossref_primary_10_3390_jcm12082922 crossref_primary_10_1016_j_ihj_2023_09_005 crossref_primary_10_1055_a_1856_2016 crossref_primary_10_1001_jamacardio_2025_0738 crossref_primary_10_1055_a_1932_6448 crossref_primary_10_1093_eurheartjsupp_suaf029 crossref_primary_10_1016_j_jacl_2024_08_011 crossref_primary_10_1161_CIRCULATIONAHA_122_061620 crossref_primary_10_1016_j_iccl_2022_12_002 crossref_primary_10_1016_j_jacc_2023_08_019 crossref_primary_10_3390_ijms241411739 crossref_primary_10_1093_eurheartj_ehae190 crossref_primary_10_3390_life13081639 crossref_primary_10_1007_s12265_024_10495_w crossref_primary_10_1007_s10554_023_02956_1 crossref_primary_10_1002_jac5_70107 crossref_primary_10_4244_EIJ_E_25_00036 crossref_primary_10_2174_1381612829666230412105238 crossref_primary_10_23736_S0392_9590_24_05266_0 crossref_primary_10_1161_CIR_0000000000001309 crossref_primary_10_1016_j_heliyon_2023_e19073 crossref_primary_10_36660_abc_20220732 crossref_primary_10_1161_ATVBAHA_123_320065 crossref_primary_10_1007_s11883_023_01112_3 crossref_primary_10_1016_j_artere_2025_100738 crossref_primary_10_1080_14712598_2024_2321374 crossref_primary_10_1016_j_jacc_2025_04_070 crossref_primary_10_1016_j_jacl_2023_06_005 crossref_primary_10_1093_cvr_cvaf019 crossref_primary_10_3389_fimmu_2024_1308978 crossref_primary_10_1016_j_jcmg_2022_11_023
ContentType	Journal Article
Contributor	Morf, Laura U Leuthard, Stefanie Rexhaj, Emrush Shibutani, Hiroki Mitter, Vera R von Eckardstein, Arnold Mayr, Manuel Goliasch, Georg Templin, Christian Tovar Forero, Maria N Pawar, Ravindra Degrauwe, Sophie Frenk, André Eberli, Franz R Ambühl, Maria Ghandilyan, Art Kaiser, Christoph Jonker, Hans Hofbauer, Thomas Sørensen, Rikke Bär, Sarah O'Sullivan, Crochan J Ten Cate, Tim Bang, Lia Kavaliauskaite, Raminta Inderkum, Andrea
Contributor_xml	– sequence: 1 givenname: Maria surname: Ambühl fullname: Ambühl, Maria – sequence: 2 givenname: Sarah surname: Bär fullname: Bär, Sarah – sequence: 3 givenname: André surname: Frenk fullname: Frenk, André – sequence: 4 givenname: Laura U surname: Morf fullname: Morf, Laura U – sequence: 5 givenname: Andrea surname: Inderkum fullname: Inderkum, Andrea – sequence: 6 givenname: Stefanie surname: Leuthard fullname: Leuthard, Stefanie – sequence: 7 givenname: Raminta surname: Kavaliauskaite fullname: Kavaliauskaite, Raminta – sequence: 8 givenname: Emrush surname: Rexhaj fullname: Rexhaj, Emrush – sequence: 9 givenname: Hiroki surname: Shibutani fullname: Shibutani, Hiroki – sequence: 10 givenname: Vera R surname: Mitter fullname: Mitter, Vera R – sequence: 11 givenname: Christoph surname: Kaiser fullname: Kaiser, Christoph – sequence: 12 givenname: Manuel surname: Mayr fullname: Mayr, Manuel – sequence: 13 givenname: Franz R surname: Eberli fullname: Eberli, Franz R – sequence: 14 givenname: Crochan J surname: O'Sullivan fullname: O'Sullivan, Crochan J – sequence: 15 givenname: Christian surname: Templin fullname: Templin, Christian – sequence: 16 givenname: Arnold surname: von Eckardstein fullname: von Eckardstein, Arnold – sequence: 17 givenname: Art surname: Ghandilyan fullname: Ghandilyan, Art – sequence: 18 givenname: Ravindra surname: Pawar fullname: Pawar, Ravindra – sequence: 19 givenname: Hans surname: Jonker fullname: Jonker, Hans – sequence: 20 givenname: Thomas surname: Hofbauer fullname: Hofbauer, Thomas – sequence: 21 givenname: Georg surname: Goliasch fullname: Goliasch, Georg – sequence: 22 givenname: Lia surname: Bang fullname: Bang, Lia – sequence: 23 givenname: Rikke surname: Sørensen fullname: Sørensen, Rikke – sequence: 24 givenname: Maria N surname: Tovar Forero fullname: Tovar Forero, Maria N – sequence: 25 givenname: Sophie surname: Degrauwe fullname: Degrauwe, Sophie – sequence: 26 givenname: Tim surname: Ten Cate fullname: Ten Cate, Tim
CorporateAuthor	PACMAN-AMI collaborators
CorporateAuthor_xml	– name: PACMAN-AMI collaborators
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1001/jama.2022.5218
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1538-3598
ExternalDocumentID	35368058
Genre	Randomized Controlled Trial Journal Article
GrantInformation_xml	– fundername: British Heart Foundation grantid: CH/16/3/32406
GroupedDBID	--- -ET -~X .55 .XZ 0R~ 0WA 186 18M 29J 2CT 2FS 2KS 2WC 354 39C 4.4 53G 5GY 5RE 6TJ 85S AAIKC AAMNW AAQQT AAWTL ABBLC ABCQX ABEHJ ABIVO ABOCM ABPMR ABPPZ ABRSH ABWJO ACAHW ACGFS ACNCT ACPRK ACQAM ADBBV ADUKH ADXHL AFCHL AFFNX AFRAH AGHSJ AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU ARBJA BKOMP BRYMA C45 CGR CJ0 CS3 CUY CVF EAM EBD EBS ECM EIF EJD EMOBN EX3 F5P H13 HF~ KOO KQ8 L7B MVM N4W N9A NEJ NPM OBH OCB OGEVE OHH OMK OVD P2P PQQKQ RAJ RNS SJN SV3 TEORI TN5 UHB UKR UPT VVN WH7 WOW X7M XHN XSW XZL YFH YOC YPV YQT YQY YR2 YR5 YSK YYM YZZ ZCA ~H1 7X8
ID	FETCH-LOGICAL-a397t-6ab5f5248fb8d0fec827a504357dea4f5de6fc57bf9739701615bef87d31c49b2
IEDL.DBID	7X8
ISICitedReferencesCount	421
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000779463700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1538-3598
IngestDate	Fri Sep 05 09:23:49 EDT 2025 Mon Jul 21 06:03:35 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	18
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-a397t-6ab5f5248fb8d0fec827a504357dea4f5de6fc57bf9739701615bef87d31c49b2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
PMID	35368058
PQID	2646941558
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2646941558 pubmed_primary_35368058
PublicationCentury	2000
PublicationDate	2022-05-10
PublicationDateYYYYMMDD	2022-05-10
PublicationDate_xml	– month: 05 year: 2022 text: 2022-05-10 day: 10
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	JAMA : the journal of the American Medical Association
PublicationTitleAlternate	JAMA
PublicationYear	2022
References	35422520 - Nat Rev Cardiol. 2022 Jun;19(6):350. doi: 10.1038/s41569-022-00706-9. 36066524 - JAMA. 2022 Sep 6;328(9):891. doi: 10.1001/jama.2022.11830. 36066523 - JAMA. 2022 Sep 6;328(9):890-891. doi: 10.1001/jama.2022.11833.
References_xml	– reference: 35422520 - Nat Rev Cardiol. 2022 Jun;19(6):350. doi: 10.1038/s41569-022-00706-9. – reference: 36066524 - JAMA. 2022 Sep 6;328(9):891. doi: 10.1001/jama.2022.11830. – reference: 36066523 - JAMA. 2022 Sep 6;328(9):890-891. doi: 10.1001/jama.2022.11833.
SSID	ssj0000137
Score	2.7332633
Snippet	Coronary plaques that are prone to rupture and cause adverse cardiac events are characterized by large plaque burden, large lipid content, and thin fibrous...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	1771
SubjectTerms	Aged Antibodies, Monoclonal, Humanized - therapeutic use Cholesterol, LDL Coronary Artery Disease - complications Coronary Artery Disease - diagnostic imaging Coronary Artery Disease - drug therapy Double-Blind Method Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Male Middle Aged Myocardial Infarction - complications Myocardial Infarction - drug therapy PCSK9 Inhibitors - therapeutic use Plaque, Atherosclerotic - complications Plaque, Atherosclerotic - diagnostic imaging Plaque, Atherosclerotic - drug therapy Treatment Outcome
Title	Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial
URI	https://www.ncbi.nlm.nih.gov/pubmed/35368058 https://www.proquest.com/docview/2646941558
Volume	327
WOSCitedRecordID	wos000779463700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1La9wwEMdFm5SSS9Nnni1T6FWtX7LkXIJZEpqDl6Vs6d4WSZaoYWMnsbew_VD9jJmxvaSXQKEXnyRbRvP4W5J_w9gnH4WxVZnniQ41TyxquMwGMU8JxW61lsKpvtiEnE7VYpHNxgW3djxWuY2JfaAuG0tr5F8wcdM_l0Ko85tbTlWjaHd1LKHxlO3GKGXIquVC_YWP6pmZvVMTqW4LbXygDkXRZ8xf6nF52aeZy_3_HeBL9mIUmJAPFvGKPXH1a_a8GLfQ37A_A68YGg_5qsL0tb7WBnKMPyV0DdC5Dz6ea-82QFq0qmE-sAegqWFCyAN9t4GcpGPT4kPwWrWAzWYDpLWFH1X3E3K77hwUG8yWZIUruKo9uhVZwhndEWb5pMinPC-u4Juuy-a6-o2DGEmlK5iTb7xl3y8v5pOvfCzawDVKm46n2ggvokR5o8oAX0hFUhMmTcjS6cSL0qXeCml8JrFDrziN80qWcWiTzETv2E7d1O6QQSh0GJhMa_poi4XGNiYmmwqMTEvnjtjH7Uws0Slop0PXrlm3y4e5OGIHw3QubwZ6xzIWcaoCoY7_ofcJ2yMb4T2t9ZTtegwJ7j17Zn91VXv3obc2vE5nxT0UeuEs
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+Alirocumab+Added+to+High-Intensity+Statin+Therapy+on+Coronary+Atherosclerosis+in+Patients+With+Acute+Myocardial+Infarction%3A+The+PACMAN-AMI+Randomized+Clinical+Trial&rft.jtitle=JAMA+%3A+the+journal+of+the+American+Medical+Association&rft.au=R%C3%A4ber%2C+Lorenz&rft.au=Ueki%2C+Yasushi&rft.au=Otsuka%2C+Tatsuhiko&rft.au=Losdat%2C+Sylvain&rft.date=2022-05-10&rft.eissn=1538-3598&rft.volume=327&rft.issue=18&rft.spage=1771&rft_id=info:doi/10.1001%2Fjama.2022.5218&rft_id=info%3Apmid%2F35368058&rft_id=info%3Apmid%2F35368058&rft.externalDocID=35368058
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-3598&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-3598&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-3598&client=summon